Vanda Pharmaceuticals (VNDA) Capital Expenditures (QoQ) (2011 - 2026)
Vanda Pharmaceuticals (VNDA) Capital Expenditures (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 315.44 Mn | 113.13 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.67% |
| Dec 31, 2025 | -36.65% |
| Sep 30, 2025 | -46.15% |
| Jun 30, 2025 | -31.42% |
| Mar 31, 2025 | 103.74% |
| Dec 31, 2024 | 32.92% |
| Sep 30, 2024 | 49.07% |
| Jun 30, 2024 | 1,442.86% |
| Mar 31, 2024 | -97.23% |
| Dec 31, 2023 | 954.17% |
| Sep 30, 2023 | -56.36% |
| Jun 30, 2023 | 7.84% |
| Mar 31, 2023 | -80.61% |
| Dec 31, 2022 | 77.70% |
| Sep 30, 2022 | -23.32% |
| Jun 30, 2022 | 157.33% |
| Mar 31, 2022 | -44.03% |
| Dec 31, 2021 | 1,440.00% |
| Sep 30, 2021 | -103.36% |
| Jun 30, 2021 | 129.23% |